Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Issam S Hamadeh

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Clinical Lymphoma, Myeloma & Leukemia|April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific AntibodiesIssam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.
JCO Oncology Practice|September 16, 2025
Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up DosesIssam S Hamadeh, Lisa Modelevsky, Amelia Chan, et al.
Blood Advances|April 10, 2024
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapyIssam S Hamadeh, Tala Shekarkhand, Colin Rueda, et al.
Blood Advances|March 6, 2025
Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up DosingCarlyn R Tan, Alice X Wang, David Nemirovsky, et al.
Blood Advances|May 2, 2025
Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed/Refractory Multiple MyelomaBenjamin O Adegbite, Carlyn Rose Tan, Tala Shekarkhand, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 17, 2020
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity ScoresCameron D Thomas, Scott A Mosley, Sarah Kim, et al.
Blood|December 1, 2020
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapyAnthony R Mato, Nilanjan Ghosh, Stephen J Schuster, et al.
JACC. Cardiovascular Interventions|November 6, 2017
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary InterventionLarisa H Cavallari, Craig R Lee, Amber L Beitelshees, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Clinical Lymphoma, Myeloma & Leukemia|April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific AntibodiesIssam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.
JCO Oncology Practice|September 16, 2025
Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up DosesIssam S Hamadeh, Lisa Modelevsky, Amelia Chan, et al.
Blood Advances|April 10, 2024
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapyIssam S Hamadeh, Tala Shekarkhand, Colin Rueda, et al.
Blood Advances|March 6, 2025
Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up DosingCarlyn R Tan, Alice X Wang, David Nemirovsky, et al.
Blood Advances|May 2, 2025
Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed/Refractory Multiple MyelomaBenjamin O Adegbite, Carlyn Rose Tan, Tala Shekarkhand, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 17, 2020
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity ScoresCameron D Thomas, Scott A Mosley, Sarah Kim, et al.
Blood|December 1, 2020
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapyAnthony R Mato, Nilanjan Ghosh, Stephen J Schuster, et al.
JACC. Cardiovascular Interventions|November 6, 2017
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary InterventionLarisa H Cavallari, Craig R Lee, Amber L Beitelshees, et al.
Pageof 3